Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 2061103Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2025
Linked Award Amount
$499.8K
Full award amounts, FY2025
Award Records
1
Records listing this PI
Award-Linked Rank
#31,804
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing David Hastings Cribbs as a PI. Multi-PI records show the full award amount for context.
- 1R44AG091903-01R44Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers$499.8Kaward amount
Award organization
Organizations that administered FY2025 awards listing David Hastings Cribbs as a PI.
FY2025 award administered by Nuravax, Inc. (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardNuravax, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #4072
- 2024Entered Top 25% NationallyRanked #4072
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as David Hastings Cribbs.